Two Sigma Investments LP Has $41.01 Million Holdings in Insmed Incorporated (NASDAQ:INSM)

Two Sigma Investments LP cut its position in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 25.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 593,996 shares of the biopharmaceutical company's stock after selling 207,143 shares during the quarter. Two Sigma Investments LP owned 0.33% of Insmed worth $41,009,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Park Avenue Securities LLC boosted its stake in shares of Insmed by 42.1% during the 4th quarter. Park Avenue Securities LLC now owns 7,955 shares of the biopharmaceutical company's stock valued at $549,000 after buying an additional 2,358 shares during the period. Atomi Financial Group Inc. raised its holdings in shares of Insmed by 6.6% during the fourth quarter. Atomi Financial Group Inc. now owns 24,774 shares of the biopharmaceutical company's stock worth $1,710,000 after acquiring an additional 1,526 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in Insmed by 5.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company's stock valued at $244,000 after purchasing an additional 183 shares during the last quarter. Avior Wealth Management LLC purchased a new position in Insmed in the fourth quarter valued at about $157,000. Finally, Blue Trust Inc. grew its stake in Insmed by 25.7% in the fourth quarter. Blue Trust Inc. now owns 2,462 shares of the biopharmaceutical company's stock valued at $180,000 after purchasing an additional 503 shares in the last quarter.

Insiders Place Their Bets

In related news, insider Martina M.D. Flammer sold 1,799 shares of the business's stock in a transaction on Friday, May 16th. The stock was sold at an average price of $67.53, for a total transaction of $121,486.47. Following the sale, the insider now owns 84,797 shares in the company, valued at $5,726,341.41. The trade was a 2.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO William Lewis sold 18,750 shares of the business's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $77.03, for a total value of $1,444,312.50. Following the sale, the chief executive officer now owns 334,186 shares in the company, valued at approximately $25,742,347.58. This trade represents a 5.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 125,211 shares of company stock worth $8,837,158 over the last three months. Insiders own 3.00% of the company's stock.

Insmed Trading Up 0.9%

NASDAQ INSM opened at $68.51 on Wednesday. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The stock's 50 day moving average price is $71.32 and its two-hundred day moving average price is $73.13. The stock has a market capitalization of $12.48 billion, a price-to-earnings ratio of -12.26 and a beta of 0.84.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The company had revenue of $92.82 million for the quarter, compared to the consensus estimate of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business's revenue was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.06) EPS. As a group, analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on INSM. Stifel Nicolaus reduced their price target on Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a report on Friday, February 21st. Jefferies Financial Group assumed coverage on shares of Insmed in a research note on Tuesday, May 13th. They issued a "buy" rating and a $105.00 target price for the company. Wells Fargo & Company increased their price target on shares of Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 19th. UBS Group cut their price target on shares of Insmed from $110.00 to $109.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Finally, Guggenheim reiterated a "buy" rating and issued a $101.00 price objective on shares of Insmed in a report on Tuesday, February 25th. One equities research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, Insmed has an average rating of "Moderate Buy" and an average target price of $94.63.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed Incorporated (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.